Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 14/20 | 0.34 |
| ▸ | TTR | P02766 | 12/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645395 | 0.82 | MGLL (0.37) | RBP4TTRKDM4E | |
| SCHEMBL23645426 | 0.75 | KDM4E (0.35) | RBP4TTRALDH1A1CNR2KDM4E | |
| SCHEMBL23645433 | 0.72 | GRM2 (0.31) | ALDH1A1KDM4E | |
| SCHEMBL23652632 | 0.71 | FFAR4 (0.32) | — | |
| SCHEMBL23645301 | 0.70 | GCGR (0.31) | RBP4KDM4E | |
| SCHEMBL23645340 | 0.70 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL23645383 | 0.69 | KMT2A (0.39) | ALDH1A1KDM4E | |
| SCHEMBL23645362 | 0.69 | KMT2A (0.39) | ALDH1A1KDM4E | |
| SCHEMBL23645417 | 0.69 | KDM4E (0.34) | ALDH1A1KDM4E | |
| SCHEMBL1423129 | 0.67 | MGLL (0.40) | PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | RBP4 3273/4885TTR 2223/4885ALDH1A1 1627/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | RBP4 3281/4885TTR 2142/4885ALDH1A1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.